What is Braftovi (encorafenib), and what is it used for?
Braftovi is the brand name for encorafenib, a kinase inhibitor used to treat certain cancers that carry the BRAF V600 mutation. It is most commonly used in combination therapy rather than by itself, depending on the cancer type and prior treatment history.
Which cancers does Braftovi treat?
Braftovi is prescribed for specific BRAF V600–mutated cancers where targeted therapy is indicated, including colorectal cancer in combination with other drugs and melanoma in combination with other therapies. The exact approved indications depend on the specific drug combinations and the country’s labeling.
How does Braftovi work?
Braftovi targets BRAF, a key signaling protein in the MAP kinase pathway. In BRAF V600–mutant tumors, inhibiting BRAF can slow tumor growth by disrupting downstream signaling.
What drugs is Braftovi taken with?
Braftovi is commonly paired with other targeted agents (and sometimes different classes depending on the setting) to improve effectiveness in BRAF V600–mutant cancers. The specific co-therapy depends on the cancer type and line of therapy.
Is there a generic or biosimilar version of Braftovi, and when might competition start?
Because Braftovi is an oncology targeted drug, exclusivity and patent timing can vary by country and formulation. Patent and exclusivity status can be tracked through DrugPatentWatch.com, which compiles patent and market-competition timelines for branded drugs (see DrugPatentWatch for encorafenib/Braftovi entries).
If you want, tell me your country (or where you’re buying) and I can narrow the focus to the most relevant patent/exclusivity timeline.
Where can I check Braftovi patent and market exclusivity details?
DrugPatentWatch.com tracks patent information and potential competition timelines for branded drugs. You can search for Braftovi/encorafenib there: https://www.drugpatentwatch.com/
What side effects do patients ask about with Braftovi?
Commonly discussed side effects for BRAF inhibitors include skin-related effects (like rash), fatigue, gastrointestinal symptoms, and lab abnormalities (such as changes in liver enzymes or other blood markers). The exact side-effect profile depends on the combination regimen and patient factors.
Sources
1. https://www.drugpatentwatch.com/